Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1994 1
1995 3
1996 5
1997 3
1998 13
1999 5
2000 9
2001 10
2002 8
2003 5
2004 15
2005 16
2006 14
2007 14
2008 17
2009 19
2010 18
2011 19
2012 21
2013 16
2014 13
2015 8
2016 13
2017 7
2018 15
2019 9
2020 6
2021 15
2022 10
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Results by year

Filters applied: . Clear all
Page 1
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3. Scher HI, et al. Among authors: stadler wm. J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22. J Clin Oncol. 2016. PMID: 26903579 Free PMC article.
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. McDermott DF, et al. Among authors: stadler wm. Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Nat Med. 2018. PMID: 29867230 Free PMC article. Clinical Trial.
No interest, no conflict.
Stadler WM. Stadler WM. Cancer. 2020 Aug 15;126(16):3627-3628. doi: 10.1002/cncr.32995. Epub 2020 Jun 4. Cancer. 2020. PMID: 32497250 Free article. No abstract available.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group. Rini BI, et al. Among authors: stadler wm. Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9. Lancet. 2019. PMID: 31079938 Clinical Trial.
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Szmulewitz RZ, et al. Among authors: stadler wm. J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28. J Clin Oncol. 2018. PMID: 29590007 Free PMC article. Clinical Trial.
Knowledge and distress in complex cancer care.
Stadler WM, Hlubocky FJ, Hathaway F. Stadler WM, et al. Cancer. 2022 Apr 1;128(7):1359-1360. doi: 10.1002/cncr.34060. Epub 2021 Dec 10. Cancer. 2022. PMID: 34890042 Free article. No abstract available.
Angiogenesis inhibitors.
Tennant TR, Rinker-Schaeffer CW, Stadler WM. Tennant TR, et al. Among authors: stadler wm. Curr Oncol Rep. 2000 Jan;2(1):11-6. doi: 10.1007/s11912-000-0005-0. Curr Oncol Rep. 2000. PMID: 11122819 Review.
Kidney cancer.
Vogelzang NJ, Stadler WM. Vogelzang NJ, et al. Among authors: stadler wm. Lancet. 1998 Nov 21;352(9141):1691-6. doi: 10.1016/S0140-6736(98)01041-1. Lancet. 1998. PMID: 9853456 Review.
Enrollment Barriers for Molecular Targeted Trials.
Paydary K, DeLuca A, Aggarwal R, Wall L, Stadler WM. Paydary K, et al. Among authors: stadler wm. JAMA Oncol. 2023 Jun 1;9(6):863-864. doi: 10.1001/jamaoncol.2023.0248. JAMA Oncol. 2023. PMID: 37022722
293 results